Baseline interleukin-10 levels as a predictive biomarker for achieving clinical response with abatacept in disease-modifying antirheumatic drug-naive and anticitrullinated protein antibody-positive patients with early rheumatoid arthritis

Rheumatoid Arthritis

Use of a Molecular Signature Response Classifier to Inform Treatment Selection Improves Clinical Disease Activity Among Patients with Rheumatoid Arthritis Initiating a Biologic or Targeted Synthetic Disease-modifying Antirheumatic Drug

Arthritis Care Res (Hoboken)

Xie F, Beukelman T, McCormick NP, Curtis JR

doi: 10.1002/acr.80010

Rheumatoid Arthritis

Incidence of major adverse cardiovascular events in patients with rheumatoid arthritis treated with Janus kinase inhibitors compared to biologic disease-modifying antirheumatic drugs: data from an international collaboration of registries (the "JAK-pot" study)

Arthritis Rheumatol

Aymon R, Mongin D, Guemara R, Salis Z, Askling J, Choquette D, Codreanu C, Di Giuseppe D, Flouri I, Huschek D, Hyrich KL, Iannone F, Kvien TK, Leeb BF, Nordström D, Otero-Varela L, Pavelka K, Pombo-Suarez M, Rodrigues A, Rotar Z, Sidiropoulos P, Provan SA, Strangfeld A, Nina T, Zavada J, Kearsley-Fleet L, Courvoisier DS, Finckh A, Lauper K

doi: 10.1002/art.43188

Rheumatoid Arthritis

Cancer risk in patients with rheumatoid arthritis receiving biologic and targeted synthetic disease modifying antirheumatic drugs: results from the BIOBADASER III registry

Rheumatology (Oxford)

Molina-Collada J, Otero-Varela L, Vela P, Manrique S, Erausquin C, Campos C, Manero J, Calvo J, Expósito L, García González J, Ruiz Montesinos MD, Rabadán E, Varela AM, Vilamajo IR, Colazo Burlato M, Plasencia C, Sánchez-Alonso F, Castrejón I, BIOBADASER Project Collaborative Group

doi: 10.1093/rheumatology/keaf556

Rheumatoid Arthritis

Incidence rates of interstitial lung disease events among patients with rheumatoid arthritis treated with abatacept or placebo, with background methotrexate: a post hoc pooled analysis from a compendium of clinical trials

Semin Arthritis Rheum

Dieudé P, Sparks JA, Fischer A, Chen L, Lozenski K, Dahan S, Chaballa M, Little W

doi: 10.1016/j.semarthrit.2025.152795

Rheumatoid Arthritis

Machine Learning Analysis of Whole-Blood Transcriptomics Data in Rheumatoid Arthritis Patients Treated with Adalimumab Identifies Predictive Biomarkers of Response

Arthritis Rheumatol

Yap CF, Nair N, Morgan AW, Isaacs JD, Wilson AG, Hyrich K, Barturen G, Riva-Torrubia M, Gut M, Gut I, Alarcón Riquelme ME, Barton A, Plant D

doi: 10.1002/art.43255

Rheumatoid Arthritis

Inflammation rather than anticitrullinated protein antibodies is associated with cardiovascular mortality in RA: insights from rheumatoid arthritis and coronary artery disease cohorts

Ann Rheum Dis

Derksen VFAM, Lindschou J, Winkel P, Delgado GE, de Moel EC, Huizinga TWJ, März W, Jakobsen JC, van der Helm-Van Mil AHM, Toes REM, Ajeganova S, Gluud C, Leipe J, van der Woude D, CLARICOR Trial Group and the LURIC Study Group

doi: 10.1016/j.ard.2025.11.023

Rheumatoid Arthritis

Progressive interstitial lung disease associated with rheumatoid arthritis and abatacept: data from a multicenter cohort of 526 patients

Rheumatology (Oxford)

Serrano-Combarro A, Atienza-Mateo B, Martín-Gutierrez A, Ibarrola Paino L, Casafont-Solé I, Loarce-Martos J, Blanco-Madrigal JM, Ortega-Castro R, Mena-Vázquez N, Fernández-Díaz C, Loricera J, Ferrer D, Castañeda S, Blanco R, Spanish Collaborative Group of Interstitial Lung Disease Associated with Rheumatoid Arthritis

doi: 10.1093/rheumatology/keag023

Rheumatoid Arthritis

Standardizing health outcomes for people with rheumatoid arthritis receiving disease modifying drug therapy: A rapid review of patient-decision aids and preference studies to inform the development of OMERACT Health Outcome Descriptors

Semin Arthritis Rheum

Raskin N, Hiligsmann M, Rebutoc AR, Bansback N, Boonen A, Buchbinder R, Falahee M, Fraenkel L, Marshall DA, Maxwell L, Nieuwlaat R, Proulx L, Saadat P, Shea B, Tugwell P, Wiercioch W, Beaton D, Richards P, Schünemann H, Guillemin F, Hazlewood GS

doi: 10.1016/j.semarthrit.2025.152769

Rheumatoid Arthritis

Achievement of treatment targets and maintenance of response with upadacitinib in patients with moderate-to-severe rheumatoid arthritis in real-world practice: 1-year outcomes from the UPHOLD observational study

Arthritis Res Ther

Östör A, Feist E, Sidiropoulos P, Avouac J, Rebella M, Namas R, McDearmon-Blondell E, Gao T, Lagunes-Galindo I, Strengholt S, Zisman D, Attar S

doi: 10.1186/s13075-025-03528-5

Related content

Use of a Molecular Signature Response Classifier to Inform Treatment Selection Improves Clinical Disease Activity Among Patients with Rheumatoid Arthritis Initiating a Biologic or Targeted Synthetic Disease-modifying Antirheumatic Drug

Incidence of major adverse cardiovascular events in patients with rheumatoid arthritis treated with Janus kinase inhibitors compared to biologic disease-modifying antirheumatic drugs: data from an international collaboration of registries (the "JAK-pot" study)

Cancer risk in patients with rheumatoid arthritis receiving biologic and targeted synthetic disease modifying antirheumatic drugs: results from the BIOBADASER III registry

Incidence rates of interstitial lung disease events among patients with rheumatoid arthritis treated with abatacept or placebo, with background methotrexate: a post hoc pooled analysis from a compendium of clinical trials

Machine Learning Analysis of Whole-Blood Transcriptomics Data in Rheumatoid Arthritis Patients Treated with Adalimumab Identifies Predictive Biomarkers of Response

Inflammation rather than anticitrullinated protein antibodies is associated with cardiovascular mortality in RA: insights from rheumatoid arthritis and coronary artery disease cohorts

Progressive interstitial lung disease associated with rheumatoid arthritis and abatacept: data from a multicenter cohort of 526 patients

Standardizing health outcomes for people with rheumatoid arthritis receiving disease modifying drug therapy: A rapid review of patient-decision aids and preference studies to inform the development of OMERACT Health Outcome Descriptors

Achievement of treatment targets and maintenance of response with upadacitinib in patients with moderate-to-severe rheumatoid arthritis in real-world practice: 1-year outcomes from the UPHOLD observational study